AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00574886 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Id-KLH
Description: Idiotype vaccine - .5mg recombinant idiotype immunoglobulin protein given subcutaneously for a total of five administrations over 6 months.
Study NCT02647749 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardioinsight® mapping system
Study NCT02647749 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional method without non-invasive mapping
Study NCT03897309 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXA-G1.1-NN
Description: Monovalent GI.1 tableted vaccine
Study NCT02084693 — intervention group
Intervention type: DEVICE
Intervention: COMPREHENSIVE
Description: Comprehensive® Reverse Shoulder products are indicated for use in patients whose shoulder joint has a grossly deficient rotator cuff with severe arthropathy and/or previously failed shoulder joint replacement with a grossly deficient rotator cuff.
Study NCT03897309 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXA-G2.4-NS
Description: Monovalent GII.4 tableted vaccine
Study NCT02672800 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the Reclaiming Yourself tool
Description: This tool is a behavioural writing intervention, intended to facilitate bereavement for spousal caregivers of persons with dementia
Study NCT01322659 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Helmet
Description: Weaning from mechanical ventilation with noninvasive positive pressure ventilation delivered by means of the helmet
Study NCT01322659 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Endotracheal tube
Description: Weaning from mechanical ventilation with invasive mechanical ventilation delivered by means of the endotracheal tube
Study NCT02107404 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cells DCVAC/PCa
Description: DCVAC/PCa Experimental therapy
Study NCT00766025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin Calcium
Description: single oral dose on days 1, 4, 5, 6, 10-16, 17
Study NCT02974478 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Orange juice with meals
Description: orange juice (20% of energy requirement/day)
Study NCT00541086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: 1 mg per day, orally
Study NCT00541086 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anastrozole
Description: 1 mg per day, orally
Study NCT03897309 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo Tablets
Description: Tablets matching in number and appearance to active vaccine doses
Study NCT03897309 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablets
Description: Tablets matching in number and appearance to active vaccine doses
Study NCT00541086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: 25 mg per day, orally
Study NCT00541086 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exemestane
Description: 25 mg per day, orally
Study NCT00541086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: 2.5 mg per day, orally
Study NCT00541086 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: letrozole
Description: 2.5 mg per day, orally
Study NCT00541086 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamoxifen citrate
Description: 20 mg per day, orally
Study NCT00386893 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: simultaneous EEG/fMRI
Description: fMRI/EEG recordings
Study NCT00386893 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: fMRI
Study NCT03270696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: administration of propofol and rocuronium
Description: compare the tidal volume applied from starting facemask ventilation under 15cmH2O of PCV for 1 minute according to administrating propofol and rocuronium simultaneously, or ordinally
Study NCT03124134 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gelesis200
Description: Encapsulated hydrogel
Study NCT03124134 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water, only (placebo)
Description: 300 mL of water
Study NCT03929809 — intervention group
Intervention type: DEVICE
Intervention: Cochlear Implant
Description: adults with unilateral hearing loss who wish to regain bilateral hearing will be implanted with a cochlear implant on their deafened ear.
Study NCT00440115 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity disease management
Description: Health education mailings, 6 motivation interviews/counseling
Study NCT00440115 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low intensity disease management
Description: Health education mailings, one motivation interview/counseling
Study NCT00440115 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Comparison group
Description: Health education mailings
Study NCT00440115 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bupropion
Description: Buproprion or Nicotine Replacement Therapy
Study NCT00440115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Buproprion or Nicotine Replacement Therapy
Study NCT00622687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iloprost
Description: 0.5-2 ng/kg x min for 6hours a day for 21 consecutive days
Study NCT00622687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iloprost low dose
Description: 0.5 ng/kg x min over 6 h per day for 21 consecutive days
Study NCT00622687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iloprost therapy up to 2 ng/kg x min
Description: starting therapy at doses of 0.5 ng/kg x min, increase the dose every two days for 0.5 ng/kg x min up to the maximally tolerated dose or to 2 ng/kg x min
Study NCT02802215 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Metformin group will receive 1500 mg of metformin per day orally ( 500 mg every 8hrs in the middle of meal) starting from 12th week of gestation till delivery.
Study NCT02802215 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (folic acid )
Description: 500 micro gram of folic acid every 8 hrs
Study NCT00183196 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: Naltrexone (50 mg/day) plus gabapentin placebo in divided doses for the first 6weeks. Naltrexone (50 mg/day) for rest of 16-weeks
Study NCT03287492 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive QPS
Study NCT03287492 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informational Intervention
Description: Receive GIS
Study NCT03287492 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03287492 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03113487 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Modified Vaccinia Virus Ankara Vaccine Expressing p53
Description: Given SC
Study NCT03113487 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT03235349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir
Description: Coformulated tablet for oral administration
Study NCT01115049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chlorobutanol, hexetidine
Description: 3 times per day (after breakfast, lunch and dinner) for 1 minute with 15 ml of mouthwash
Study NCT01115049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: 3 times per day (after breakfast, lunch and dinner) for 1 minute with 15 ml of mouthwash
Study NCT03502278 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Islamic Trauma Healing
Description: A lay-led, six-session group intervention that combines empirically supported exposure-based and cognitive restructuring techniques with Islamic principles
Study NCT02341989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin Etoposide and Cisplatin
Study NCT02341989 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Study NCT02345252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/RPV/TAF
Description: 200/25/25 mg FDC tablets administered orally once daily
Study NCT02345252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/RPV/TDF Placebo
Description: Tablets administered orally once daily
Study NCT02345252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FTC/RPV/TDF
Description: 200/25/300 mg FDC tablets administered orally once daily
Study NCT02345252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FTC/RPV/TAF Placebo
Description: Tablets administered orally once daily
Study NCT02515864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FYU-981
Study NCT02515864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02515864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT02515864 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02515864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Study NCT02515864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Placebo
Study NCT02515864 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin Placebo
Study NCT04156750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3556050
Description: Administered orally.
Study NCT00183196 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone plus Gabapentin
Description: naltrexone (50 mg/day) for 16-weeks plus gabapentin (up to 1200 mg/day in divided doses) for the first 6 weeks
Study NCT00183196 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Inactive Placebo
Description: Placebo
Study NCT03239496 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPV
Description: Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)
Study NCT03239496 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: f-IPV
Description: Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)
Study NCT01235715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Evicel fibrin sealant
Description: Used for hemostasis to control bleeding. It has been shown to stop bleeding in 2 minutes or less. It is a combination of a biologic activated component containing human fibrinogen and topical thrombin functioning on wet, actively bleeding tissue.
Study NCT02074267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbatin
Description: Carbatin® or Neurontin® is initiated at 100 mg at night and slowly titrated to 300\~800 mg three times/day over 4 to 25 days.~The dose of Carbatin® or Neurontin® taken by each patient will amount to 100 to 2400 mg /day oral if the pain intensity reaches a VAS score ≧4. The maintenance dose of Carbatin® or Neurontin® will throughout for at least 14 days of the treatment period.
Study NCT02074267 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neurontin
Description: Carbatin® or Neurontin® is initiated at 100 mg at night and slowly titrated to 300\~800 mg three times/day over 4 to 25 days.~The dose of Carbatin® or Neurontin® taken by each patient will amount to 100 to 2400 mg /day oral if the pain intensity reaches a VAS score ≧4. The maintenance dose of Carbatin® or Neurontin® will throughout for at least 14 days of the treatment period.
Study NCT00403949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azelaic acid 15% gel
Description: gel, applied once daily, for 6 weeks
Study NCT00403949 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Non-active base from azelaic acid 15% gel
Description: gel, apply once daily for six weeks
Study NCT04533906 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coldamaris lozenges
Description: sucking carageenan containing lozenge
Study NCT01074645 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Tenofovir disoproxil fumarate (TDF)
Description: Tenofovir 300mg/day for 3 month
Study NCT01074645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil fumarate (TDF)
Description: Tenofovir 300mg/day for 3 month
Study NCT02733627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1467335
Study NCT02733627 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02576717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPC1063
Study NCT03255863 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: Patient Self reported questionnaire filled in.
Study NCT01177163 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: one placebo capsule once daily for 3 days immediately prior to randomization to double-blind treatment with JNJ 28431754 or placebo
Study NCT01177163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 28431754 300 mg/placebo
Description: one 300-mg capsule of JNJ-28431754 or placebo twice-daily for 4 weeks
Study NCT01177163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 28431754 100 mg/placebo
Description: one 100-mg capsule of JNJ-28431754 or placebo once-daily for 4 weeks
Study NCT02079337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Study NCT02079337 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rocuronium
Study NCT02079337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sugammadex
Study NCT02079337 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugammadex
Study NCT02079337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Study NCT02079337 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00406016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI355
Study NCT00768352 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Educational intervention
Description: An educational intervention which will consist of a standardized PowerPoint presentation that will cover general mental health topics such as depression and substance abuse. The presentation will also include discussion of common and validated mental health screening and assessment tools, as well as how to use these tools in a clinical setting. An educational packet will be provided to the residents and will include the screening tools, information on motivational interviewing and the behavioral stages of change, information on common medications prescribed for mental health disorders, and a bibliography of reputable resources for mental health topics.
Study NCT03658863 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic ultrasound
Description: Evaluation of bile ducts with endoscope with special ultrasonographic function
Study NCT03658863 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intraoperative cholangiography
Description: evaluation of bile ducts by injecting radiocontrast media to cystic duct during laparoscopic cholecystectomy
Study NCT03658863 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP
Description: evaluation of bile ducts by injecting radiocontrast media to common bile duct via endoscope inserted to duodenum
Study NCT03658863 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound endoscope
Description: Endoscope with built-in ultrasound function
Study NCT02553655 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 4x 5min Limb Preconditioning
Description: A blood pressure cuff is placed over the upper thigh of the participant(s) and inflated to 30 millimeters of mercury (mmHg) above systolic blood pressure. The loss of pedal pulses is confirmed by palpation. The cuff remains inflated for 5min and is followed by 5 minutes of reperfusion/rest. This will be repeated 4 times.
Study NCT02553655 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3x 10min Limb Preconditioning
Description: A blood pressure cuff is placed over the upper thigh of the participant(s) and inflated to 30 mmHg above systolic blood pressure. The loss of pedal pulses is confirmed by palpation. The cuff remains inflated for 10min and is followed by 5 minutes of reperfusion/rest. This will be repeated 3 times.
Study NCT02553655 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: 3x 10min Sham Preconditioning
Description: A blood pressure cuff is placed over the upper thigh of the participant(s) and inflated to 40 mmHg, sufficient to apply pressure but not affect blood flow. The presence of pedal pulses is confirmed by palpation. The cuff remains inflated for 10min and is followed by 5 minutes of rest. This will be repeated 3 times.
Study NCT01858987 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stapler hepatectomy
Description: Liver resection using vascular stapler for transection of the parenchyma
Study NCT01858987 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LigaSure hepatectomy
Description: Liver resection using LigaSure for transection of the parenchyma
Study NCT01858987 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ligasure
Study NCT01858987 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: vascular staple
Study NCT03877926 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV7909
Description: AV7909 consists of Anthrax Vaccine Adsorbed (AVA) drug substance and CPG 7909 adjuvant. AVA drug substance in AV7909 is similar in composition and manufactured using the same process as commercial BioThrax® vaccine. BioThrax is licensed for post-exposure prophylaxis of anthrax disease. CPG 7909 is an immunostimulatory synthetic oligodeoxynucleotide that functions as an adjuvant. It is designed to induce an enhanced immune response.
Study NCT03877926 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BioThrax
Description: BioThrax vaccine (Anthrax Vaccine Adsorbed; AVA) is licensed for post-exposure prophylaxis of anthrax disease.
Study NCT02588079 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy
Study NCT02268539 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ablation
Description: Ablation ranging from 20-25 watts / 30-45 seconds
Study NCT03245307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib at a dosage of 750mg will be administered daily from day 9 of phase A
Study NCT03245307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine GTIS
Description: Nifedipine at a dosage of 30mg will be administered at day 1 and day 14 of phase A
Study NCT03245307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin Potassium
Description: Nifedipine at a dosage of 3mg will be administered at day 3 and day 16 of phase A
Study NCT03554317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone cypionate
Description: Depot (DEPO)-Testosterone Injection, for intramuscular (IM) injection, contains testosterone cypionate which is the oil-soluble 17 (beta)-cyclopentylpropionate ester of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. Depot (DEPO)-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate.
Study NCT03554317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab Injection, 100 mg/10 mL (10 mg/mL) or 40 mg/4 mL (10 mg/mL), is a clear to opalescent, colorless to pale yellow liquid, which may contain light (few) particulates. The drug product is a sterile, non-pyrogenic, single-use, isotonic aqueous solution formulated at 10 mg/mL in sodium citrate, sodium chloride, mannitol, diethylenetriaminepentacetic acid (pentetic acid), and polysorbate 80 (Tween 80), at potential hydrogen (pH) 6.0 and includes an overfill to account for vial, needle, and syringe holdup. It is supplied in 10-cc Type I flint glass vials, stoppered with butyl rubber. The clinical study product is a sterile solution to be administered through parenteral intravenous infusion.
Study NCT03297619 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness and Acceptance Workbook for Social Anxiety and Shyness
Description: Participants assigned to this condition will be asked to read this self-help book over an 8-week period.
Study NCT03297619 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The Shyness and Social Anxiety Workbook
Description: Participants assigned to this condition will be asked to read this self-help book over an 8-week period (with some chapters omitted).